Garcinoic acid: A vitamin E metabolite-mimetic scaffold linking nuclear receptor pharmacology to inflammatory signaling and biomimetic drug discovery.

Long-chain metabolites produced through hepatic and microbiota-associated ω-oxidation of vitamin E are increasingly recognized as bioactive regulators of lipid metabolism and inflammatory pathways. These properties suggest interesting opportunities in drug development and garcinoic acid (GA) - a δ-tocotrienol-derived natural product and a chemically accessible analogue of these metabolites - is a useful probe for investigating their molecular and pharmacological properties. GA has been identified as an agonist of pregnane X receptor, a modulator of peroxisome proliferator-activated receptor γ, and an inhibitor of enzymes involved in biosynthesis of inflammatory lipid mediators, including 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1, while its effects on cyclooxygenase pathways are context-dependent. Through these activities, GA functionally links xenobiotic sensing, lipid metabolism, and inflammatory regulation across selected tissues, including the intestine, liver and brain. GA can be viewed within the broader framework of metabolite-inspired pharmacology, highlighting how plant-derived natural products that mimic endogenous or microbiota-associated metabolites may carry privileged recognition motifs for pharmacological targets. These aspects, together with the biological effects of GA identified in preclinical models, suggest therapeutic potential. However, direct applications are constrained by unfavorable pharmacokinetic properties, supporting its use as a biomimetic scaffold for the design of improved modulators inspired by vitamin E metabolite biology.